TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05628610
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel: 150mg / m2 ,d1, q3w
Study: NCT05628610
Drug: Platinum: cisplatin, carboplatin, naidaplatin and other platinum drugs
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin, carboplatin, naidaplatin and other platinum drugs
Study: NCT06494475
Drug: Tdap vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection.
Study: NCT05405751
Drug: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
Normalized name: Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients enrolled in the study and accessing the HIV consultation will start treatment with BIKTARVY on the day of enrollment. Medication will be provided by the sponsor and dispensed through the pharmacy service. The drug will be delivered to the patient with a delegated person outside the hospital environment or it will be the patient himself who picks up the medication.
Study: NCT04879992
Drug: Esomeprazole
Normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proton pump inhibitor
Study: NCT04879992
Drug: Bismuth Potassium Citrate
Normalized name: bismuth
DrugBank: Bismuth cation (DB14572)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric mucosal protective drug with anti-H. pylori effect
Study: NCT04879992
Drug: amoxicillin rifabutin
Normalized name: AMOXICILLIN/OMEPRAZOLE/RIFABUTIN
DrugBank: Rifabutin (DB00615)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics for H. pylori eradication
Study: NCT04149821
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Lead-in cycle of 28 days (Cycle -1) of umbralisib monotherapy, 800mg oral daily~* Continued 800mg oral daily dosing in all subsequent cycles (combination therapy cycles 1-6, then continued monotherapy cycle 7 and beyond)
Study: NCT04149821
Drug: Ublituximab
Normalized name: Ublituximab
DrugBank: Ublituximab (DB11850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -Co-administered on days 1 and 2 (dose split over days 1 and 2), 8, 15 of cycle 1 then on day 1 for subsequent cycles 2-6
Study: NCT05867030
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenalidomide is administered orally
Study: NCT05867030
Drug: rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: rituximab is administered intravenously
Study: NCT05867030
Drug: parsaclisib
Normalized name: Parsaclisib
DrugBank: Parsaclisib (DB14867)
Approvals — FDA: no, EMA: no, PMDA: no
Description: parsaclisib is administered orally
Study: NCT06301438
Drug: dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalpiciclib oral day 1-21, every 28 days
Study: NCT06015724
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-CD38 monoclonal antibody (mAb)
Study: NCT06015724
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-PD-1 (programmed cell death protein 1) monoclonal antibody (mAb)
Study: NCT04842331
Drug: RESP301 (a nitric oxide generating solution)
Normalized name: Nitric Oxide
DrugBank: RESP301 (DB16497)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration is simple and convenient; each dose of RESP301 is administered 3 times daily (at least 4 hours apart) via inhalation using a portable handheld vibrating mesh nebuliser for approximately 8-10 minutes.
Study: NCT04784091
Drug: TP-03
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TP-03, lotilaner ophthalmic solution, 0.25%, administered twice a day
Study: NCT04784091
Drug: TP-03 Vehicle
Normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Vehicle of TP-03 ophthalmic solution, administered twice a day
Study: NCT04395456
Drug: AMY-101
Normalized name: AMY-101
DrugBank: AMY-101 (DB14803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C3 complement inhibitor
Study: NCT04790903
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will self-administer Venetoclax, as described in the Arm Descriptions.
Study: NCT04790903
Drug: Polatuzumab Vedotin
Normalized name: polatuzumab vedotin
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Polatuzumab Vedotin at a dose of 1.8 mg/kg by intravenous (IV) infusion on Day 1 of Cycles 1-6.
Study: NCT04790903
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Rituximab at a dose of 375 mg/m\^2 by IV infusion on Day 1 of Cycles 1-6.
Study: NCT04790903
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive Prednisone orally (PO) at a dose of 100 mg/day on Days 1-5 of Cycles 1-6.
Study: NCT05773105
Drug: Cadonilimab+regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: cadonilimab(10mg/kg, iv,Q3W,D1) + regorafenib(80mg,PO,QD,everyday)
Study: NCT06575322
Drug: Carboplatin（ neoadjuvant）
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (IV), AUC=5，administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT06575322
Drug: Paclitaxel （neoadjuvant）
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 260mg/m2 administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study: NCT05669950
Drug: Lu AG13909
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for infusion
Study: NCT00000971
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000971
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05636904
Drug: prostaglandin F2a analogue in vehicle solution high dose
Normalized name: Prostaglandin F2a tromethamine
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for 24 weeks
Study: NCT05636904
Drug: prostaglandin F2a analogue in vehicle solution low dose
Normalized name: Prostaglandin F2a tromethamine
DrugBank: Dinoprost tromethamine (DB01160)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment for 24 weeks
Study: NCT05636904
Drug: Minoxidil 5% Topical Solution
Normalized name: Minoxidil 5% Topical solution
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical treatment for 24 weeks
Study: NCT02136511
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib 150 mg tablet administered orally twice daily
Study: NCT02136511
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab administered intravenously starting at 375 mg/m\^2 at Week 0 and continuing with a dose of 500 mg/m\^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
Study: NCT04709913
Drug: HU6
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HU6 is designed to reduce the steatosis, inflammation, fibrosis and hepatocyte injury in Noncirrhotic Nonalcoholic Steatohepatitis (NASH)
Study: NCT06550336
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 mg (4 tablets) twice a week, specifically on days 1, 4, 8, 11, 15, 18, 22, and 25.Each 4-week period constitutes one treatment cycle.
Study: NCT04656288
Drug: BI 764198 - Formula A
Normalized name: Combretastatin A-1 bis(phosphate)
DrugBank: OXI-4503 (DB05143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT04656288
Drug: BI 764198 - Formula C
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 764198
Study: NCT04656288
Drug: BI 764198 - Formula D
Normalized name: calcium bis[(2ξ)-D-glycero-D-gulo-heptonate]
DrugBank: Calcium glucoheptonate (DB00326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BI 764198
Study: NCT05522192
Drug: Mitoxantrone liposome
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase I: 24mg/m2, 30 mg/m2, 36mg/m2, IV, d1; Phase II: RP2D.
Study: NCT05522192
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase I/II: 100mg po d1，200mg po d2，400mg po d3-28.
Study: NCT05383131
Drug: HEC585
Normalized name: Hec585
DrugBank: Yinfenidone (DB18330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mulltiple doses of HEC585 for up to 10 days
Study: NCT05383131
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mulltiple doses of Pirfenidone for up to 3 days
Study: NCT05383131
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Mulltiple doses of Nintedanib for up to 7 days
Study: NCT05095116
Drug: APT-1011 3 mg HS
Normalized name: tetracycline
DrugBank: APT-101 (DB18003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.
Study: NCT04521881
Drug: Tranexamic Acid 500 MG
Normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: given once as an intramuscular injection
Study: NCT06414941
Drug: Dexmedetomidine administration
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Study: NCT06414941
Drug: Dexmedetomidine plus low-dose esketamine administration
Normalized name: ethinyl estradiol
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT06414941
Drug: Dexmedetomidine plus high-dose esketamine administration
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study: NCT05969184
Drug: CDK4/6 inhibitor (Qilu),Trastuzumab (Hanquyou)
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CDK4/6 inhibitor (Qilu) have got the cFDA approval and Trastuzumab (Hanquyou) have few data on combination use, this two drugs need clinical treatment data
Study: NCT04814472
Drug: BLD-0409
Normalized name: BLD-0409
DrugBank: Cudetaxestat (DB18203)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized to active product.
Study: NCT00051090
Drug: Telbivudine
Normalized name: Telbivudine
DrugBank: Telbivudine (DB01265)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally at a daily dosage of 600 mg for a period of 48 weeks
Study: NCT00051090
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally at a total daily dosage of 300 mg for Weeks 24-48
Study: NCT00051090
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally at a daily dose of 600 mg
Study: NCT00051090
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
Study: NCT00051090
Drug: Abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered orally twice daily in doses of 300 mg
Study: NCT00439504
Drug: Lobeline
Normalized name: lobeline
DrugBank: Lobeline (DB05137)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05843305
Drug: BPI-452080
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive BPI-452080 until disease progression
Study: NCT06238011
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine(Precedex Pfizer) prepared in concentration 0.1 mcg/kg/ml total volume50 ml by nurse anesthetist at preprocedure room, start dexmedetomidine by anesthesiologist at operating room loading 60 ml/hour for 10 minutes before induction of anesthesia then 5ml/hour until the patient on cardiopulmonary bypass (loading 1mcg/kg in 10 minutes then 0.5 mcg/kg/hour). Record patients data by nurse anesthetist
Study: NCT04135677
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Drug: Rivaroxaban 20mg Duration of treatment: 12 weeks(12 weeks for DAPT afterwards)
Study: NCT04135677
Drug: DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Aspirin 100mg and clopidogrel 75mg Duration of treatment:24 weeks
Study: NCT04629495
Drug: Rapamycin
Normalized name: Rapamycin
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAPA will be administered orally 1mg daily
Study: NCT03613181
Drug: ANG1005
Normalized name: ANG1005
DrugBank: ANG1005 (DB18167)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug
Study: NCT04776629
Drug: Orticumab
Normalized name: Orticumab
DrugBank: Orticumab (DB16653)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A human recombinant monoclonal antibody against a specific oxidized low-density lipoprotein (oxLDL) epitope
Study: NCT04487613
Drug: Moringa oleifera leaf
Normalized name: MORINGA OLEIFERA LEAF
DrugBank: Moringa oleifera leaf (DB14362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg capsule
Study: NCT04982575
Drug: Semaglutide 2.4 mg
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Semaglutide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT04982575
Drug: Cagrilintide 2.4 mg
DrugBank: Cagrilintide (DB18887)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cagrilintide administered s.c. (subcutaneously, under the skin) once weekly. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 32 weeks
Study: NCT05089383
Drug: Utrogestan
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PROSPECTIVE STUDY
Study: NCT05430243
Drug: Empagliflozin 10 MG
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: once daily empagliflozin 10mg+/- diuretics
Study: NCT05994339
Drug: Almonertinib
Normalized name: Almonertinib
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy was administered using Intensity-Modulated Radiation Therapy (IMRT) technique, with a prescribed dose of 60 Gy in 30 fractions. Almonertinib was orally administered at 110 mg per day, starting from the first day of radiotherapy and continued for 42 days until the completion of radiotherapy, followed by continuous medication until disease progression.
Study: NCT05202314
Drug: Immunotherapy (Camrelizumab)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After clinical success of colonic stenting, regardless of the MSI state, patients will receive Immunotherapy (Camrelizumab 200mg) for 2 cycles compined with neoadjuvant chemotherapy with mFOLFOX6 regimen for 3 cycles or CapeOx regimen for 2 cycles. Patients will undergo surgery 2-3 weeks after the last cycle chemotherapy
Study: NCT04427540
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin 10 micrograms IM
Study: NCT01606358
Drug: Carboplatin and / or taxol chemotherapy
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
Study: NCT05068180
Drug: low-dose neuroleptanalgesia
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Droperidol 1.25 mg and fentanyl 0.025 mg (diluted with normal saline up to 5ml) is to be administrated intravenously 30 minutes before the end of the procedure.
Study: NCT05339373
Drug: Aceclofenac film-coated tablet 100 mg
Normalized name: aceclofenac
DrugBank: Aceclofenac (DB06736)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aceclofenac is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 100 mg of aceclofenac.
Study: NCT04712799
Drug: Otrivin
Normalized name: Otrivin
DrugBank: Xylometazoline (DB06694)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxymetazoline nasal spray
Study: NCT05715944
Drug: AZD 1222
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine
Study: NCT06229067
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab at a dose of 1200 mg via intravenous infusion every three weeks. Adebrelimab will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT06229067
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine 20 mg every other day. Vinorelbine will continue to be administered as long as patient experiences clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
Study: NCT00038272
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00038272
Drug: Amdoxovir
Normalized name: Amdoxovir
DrugBank: Amdoxovir (DB06619)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04313088
Drug: Eluxadoline 100 mg
Normalized name: eluxadoline 100 MG
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eluxadoline 100mg by mouth twice daily with food
Study: NCT04760977
Drug: Drugs administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antifibrinolytics, analgesics, sedatives, neuromuscular blocking agents
Study: NCT04948814
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg/kg/day
Study: NCT05183841
Drug: Bronchodilator (Ipratropium and Fenoterol)
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 puffs of Ipratropium (20mcg) and Fenoterol (50mcg) via an inhaler device with a spacer (30 seconds interval between puffs) in 5 tidal volume breaths each puff.
Study: NCT06555575
Drug: Ubiquinol 100 MG Oral Capsule
Normalized name: ubiquinol 100 mg oral capsule
DrugBank: Ubiquinol (DB11340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth three times daily for three months
Study: NCT00213109
Drug: Miglitol
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05782933
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab combined with or without cyclosporine
Study: NCT05635370
Drug: Pentoxifylline
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline claim is used as the exposure group.
Study: NCT05635370
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol claim is used as the reference group.
Study: NCT06521996
Drug: CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
Normalized name: ethanol
DrugBank: Trichophyton mentagrophytes (DB10446)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cyclophosphamide will be administered at a dose of 750 mg/ m2 IV on Day 1 of Cycle 1-6, every 21 days.~Doxorubicin will be administered at a dose of 50 mg/m2 IV on Day 1 of Cycle 1-6, during induction treatment.~Vincristine will be administered at a dose of 1.4 mg/m2 (maximum 2 mg) IV infusion in 50 ml sodium chloride 0.9% over 10 minutes on Day 1 of Cycle 1-6, every 21 days.~Methylprednisolone will be administered at fixed dose of dose 80 mg IV on Day 1 of Cycle 1-6, every 21 days.~Prednisone will be administered at a dose of 60 mg/m2 orally on Days 2-5 of Cycle 1-6, every 21 days.
Study: NCT05191290
Drug: unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: standard heparin at 2500 IU i.v. bolus and then 2000 IU/h continuously i.v. for anticoagulation during plasmapheresis
Study: NCT05191290
Drug: Sodium Citrate
Normalized name: Sodium Citrate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8% sodium citrate at approx. 27 mmol/h i.v. for anticoagulation during plasmapheresis
Study: NCT04924192
Drug: Anlotinib Hydrochloride capsules
Normalized name: loperamide hydrochloride Oral Capsule
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A multi-target receptor tyrosine kinase inhibitor
Study: NCT04924192
Drug: Irinotecan Hydrochloride for Injection
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: An inhibitor of DNA topoisomerase Ⅰ